2009年

November 5, 2009: Execution of License Agreement on Neramexane for Tinnitus with Merz Pharmaceuticals for Japan Territory
September 29, 2009: KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos® Tablets in China, India, Sri Lanka and ASEAN Countries
August 5, 2009: First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2010
July 27, 2009: Grant of Marketing Right to Senju Pharmaceutical on Gatifloxacin Ophthalmic Solution in China
April 3, 2009: Change of Representative Director and President at KYORIN Pharmaceutical
April 3, 2009: Change of Representative Director and President at KYORIN
March 19, 2009: KYORIN Announces Dissolution of Subsidiary
March 19, 2009: KYORIN Subsidiary (Investment LPS) to Be Dissolved
February 27, 2009: Execution of Licensing and Supply Agreement on Uritos® Tablets with SPIMACO
February 5, 2009: Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2009
February 4, 2009: KYORIN Updates Credit Rating from R&I
January 29, 2009: Paper on Clinical Trial of MUCODYNE® for COPD Patients (PEACE Study) Chosen for THE LANCET Paper of the Year 2008